Delivering quality therapy since 1901
  • Press releases

    Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter

    Budapest (Hungary) and Cranbury, NJ (USA) – 3 September 2014 – Palatin Technologies, Inc. (NYSE MKT: PTN; hereinafter: "Palatin") and Gedeon Richter Plc. (hereinafter: "Richter") announced that they have entered into a collaboration and license agreement,  to co-develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the European Union, other European countries and additional selected countries.  Richter is a European-based specialty pharmaceutical company with a strong focus in female health and annual sales of more than EUR1.2 billion (US$1.6 billion).

  • in Focus

    Gynaecology

    Gynaecological therapy is a focus area for Richter. The company has several decades of unparalleled experience in this area. The first steroid experiments were conducted by the company’s founder, Gedeon Richter himself. Our company was the first pharmaceutical company to put a contraceptive on the Hungarian market, in 1966.

  • Central Nervous System
  • Cardiology
Loading...

​​​​​ ​​​​​ ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​